Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rapid venom immunotherapy update.

Troy A Scribner1, David I Bernstein

  • 1Cincinnati Children's Hospital, Division of Allergy and Medical Center, Cincinnati, Ohio 45267, USA.

Current Opinion in Allergy and Clinical Immunology
|July 17, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of serum antibodies as correlates of protection against norovirus infection and disease.

The Journal of infectious diseases·2026
Same author

Efficacy of Epinephrine Nasal Spray in the Treatment of Urticaria.

The journal of allergy and clinical immunology. In practice·2026
Same author

Pharmacokinetics and Pharmacodynamics Following Repeat Dosing of neffy (Epinephrine Nasal Spray) Versus Intramuscular Injection During Induced Allergic Rhinitis.

The journal of allergy and clinical immunology. In practice·2026
Same author

Real-world data on the effectiveness of neffy in clinical practice.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2025
Same author

Immunotherapy in Allergic and Mixed Rhinitis.

Immunology and allergy clinics of North America·2025
Same author

Impact of Dose Adjustment After Gaps in Subcutaneous Immunotherapy: Update From the North American Immunotherapy Surveillance Study (2008-2023).

The journal of allergy and clinical immunology. In practice·2025
Same journal

Biosimilars in allergology: an outline in pediatric patients.

Current opinion in allergy and clinical immunology·2026
Same journal

The immunogenetic landscape of systemic lupus erythematosus.

Current opinion in allergy and clinical immunology·2026
Same journal

Circadian control of innate immunity: molecular mechanisms and implications for allergic disorders.

Current opinion in allergy and clinical immunology·2026
Same journal

Probiotics in allergic disease: from adjunct supplement to immune-modifying strategy (2026 update).

Current opinion in allergy and clinical immunology·2026
Same journal

Updates on drug-induced anaphylaxis in children.

Current opinion in allergy and clinical immunology·2026
Same journal

Beta-lactam de-labelling as a core antimicrobial stewardship strategy in the era of the antimicrobial resistance pandemic: a narrative review.

Current opinion in allergy and clinical immunology·2026
See all related articles

Rapid or ultrarush venom immunotherapy, using antihistamine pretreatment, offers a safe and effective way to achieve high maintenance doses quickly. This approach may improve outcomes and reduce reactions in patients undergoing venom immunotherapy.

Area of Science:

  • Allergy and Immunology
  • Clinical Medicine

Background:

  • Venom immunotherapy (VIT) is a crucial treatment for Hymenoptera venom allergy.
  • Conventional VIT protocols require prolonged treatment durations.
  • Rapid and ultrarush VIT protocols aim to accelerate the achievement of therapeutic venom doses.

Purpose of the Study:

  • To review new indications for rapid/ultrarush venom immunotherapy.
  • To evaluate the advantages of antihistamine pretreatment in VIT.

Main Methods:

  • Review of recent literature on rapid and ultrarush venom immunotherapy protocols.
  • Analysis of systemic reaction rates associated with these protocols.
  • Assessment of the role of antihistamines in mitigating reactions.

Related Experiment Videos

Main Results:

  • Rapid and ultrarush VIT protocols effectively achieve protective venom doses rapidly with low systemic reactor rates (5-7%).
  • These protocols can achieve ultra-high maintenance doses for patients refractory to standard doses.
  • Antihistamine pretreatment may reduce injection-related and long-term systemic reactions.

Conclusions:

  • Antihistamine pretreatment should be considered for patients undergoing rapid/ultrarush VIT.
  • Rapid/ultrarush VIT regimens are comparable to conventional protocols regarding side effects.
  • These accelerated protocols can be beneficial for achieving higher maintenance doses in treatment-resistant cases.